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ABSTRACT 
 
The purpose of this study was to evaluate the performance of Neusilin®  (NEU) a synthetic 
magnesium aluminometasilicate as inorganic drug carrier co-processed with the hydrophilic 
surfactants Labrasol and Labrafil to develop Tranilast (TLT) based solid dispersions using 
continuous melt extrusion (HME) processing.  Twin – screw extrusion was optimized to 
develop various TLT/excipient/surfactant formulations followed by continuous capsule filling 
in the absence of any downstream equipment. Physicochemical characterisation showed the 
existence of TLT in partially crystalline state in the porous network of inorganic NEU for all 
extruded formulations. Furthermore, the in line NIR studies revealed a possible 
intermolecular H–bonding formation between the drug and carrier resulting in the increase of 
dissolution of TLT. The capsules containing TLT extruded solid dispersions showed 
enhanced dissolution rates and compared with the marketed Rizaben® product.  
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Introduction 
Today pharmaceutical industry undergoes a transition from conventional batch 
manufacturing production to continuous processing. Due to market globalization, 
pharmaceutical industries are facing immense challenges to comply with the demands of 
regulatory agencies while the reduced patent life and overall decreased profitability of newly 
discovered drug substances forces them to shorten the drug development times with 
maximum throughput. Therefore, continuous manufacturing processes (CM) can be proved 
an efficient and promising alternative for achieving these goals. 1 CM provides better product 
quality assurance than batch process with less labour cost and time for development. 
Furthermore, strong efforts are taken on the implementation of process analytical tools (PAT) 
for the purposes of in-line process monitoring and quality control. 2-4  
To date, hot melt extrusion (HME) has been utilised to a great extent for the development 
and optimisation of solid dispersions 5-14 in order to enhance the dissolution rate of water 
insoluble drugs.15-16 Although HME is a versatile technology and can be used for continuous 
manufacturing of various pharmaceutical dosage forms, it has not yet fully exploited for such 
purposes. Continuous HME offers several advantages such as small footprint, cost efficiency, 
reduced material waste and coupling with various process analytical tools (PAT).   
The processing of inorganic excipients 17, 18 as drug carries to increase dissolution rates of 
water insoluble drugs has recently gain interest for the development of solid dispersions. Bahl 
et al., evaluated the solubility and dissolution profiles of the poorly water-soluble drug 
indomethacin co-processed with Neusilin, an inorganic carrier 19 using ball-milling 
micronization. The author found that the presence of silicic acid and Mg2+/Al3+ions, of NEU 
in the dissolution media increased the concentration of indomethacin and enhanced its in 
vitro dissolution rates. Maclean et al. (2011), described a robust extrusion process involving 
hot melt extrusion to form a Sulindac-NEU amorphous drug complex to enhance the 
dissolution rate of sulindac. 20   
Recently, Maniruzzaman et al., conducted extrusion studies to assess the performance of 
synthetic magnesium aluminometasilicate as an inorganic carrier for the development of 
stable indomethacin (IND) solid dispersions. Several IND/NEU blend ratios (20%, 30% and 
40%) were extruded continuously using a twin - screw extruder resulting in enhanced drug 
dissolution rates while the solid dispersions were stable over 12 months. 21 The same group 
reported another study of an extrusion granulation process for the increased dissolution of the 
water insoluble ibuprofen (IBU). A quality-by-design (QbD) approach was implemented 
  
through a design of experiment to produce IBU loaded granules. The extruded granules 
showed significant enhancement in the dissolution profiles of ibuprofen attributed to the 
intermolecular interactions of the drug and the inorganic carrier. 22  
 Neusilin® (NEU) is considered a synthetic magnesium aluminometasilicate 23 that 
exhibits exceptional physical properties for improved drug delivery (e.g. high specific surface 
area, high flowability, amorphous). Tranilast is classified as a BCS class II drug with 
solubility in water and acidic medium (pH 1.2) of 14.5 and 0.7 µg/mL, respectively. 24, 25  
Up to date most of the research focuses on the HME processing of polymers, lipids or 
inorganic excipients as single drug carriers. Herein we present a two-fold study where 
inorganic excipients are co-processed with a variety of surfactant/solubilizers to produce 
stable solid lipid dispersions with enhanced drug dissolution rates. In addition HME 
processing was optimized for continuous manufacturing of TLT capsules by direct feeding of 
the extruded formulations in a capsule-filling machine.  
 
Materials and method 
Materials 
Tranilast (TLT) (≥ 98%) was purchased from Tokio Chemical Industries (Japan) and 
Neusilin (NEU) (≥ 99%) was kindly donated by Fuji Chemical Industries Co., Ltd. (Japan). 
Labrasol (LSOL) (≥ 98%) and Labrafil (LFIL) (≥ 98%) were kindly donated by Gattefosse, 
France. All solvents used were of analytical grade and used as received. 
 
Solubility study of TLT is surfactants 
Phase solubility study was performed to know the solubility of TLT in the presence of 
various surfactants in buffer solution (pH 6.8). An excess quantity of TLT was placed in 20 
ml tube containing 10 ml of buffer medium with 1-5% surfactants (w/w). All test tubes were 
subjected to sonication for 20 min at room temperature followed exposure to orbital shaking 
thermo stable incubator (Boekel Scientific, Germany) for 48 h at 37±0.5°C with rotating 
speed of 75 agitations /min. The supernatant solution was then passed through a Whatman 
filter Paper (Grade 1) and analyzed by HPLC to quantify the amount of TLT dissolved. The 
best two surfactants were chosen to undertake further experiments.  
 
 
 
  
Continuous hot-melt extrusion processing and manufacturing of capsules 
All prepared binary or ternary mixtures with either LSOL or LFIL as surfactant were 
extruded at temperatures varying form 170–200oC to find the suitable extrusion temperatures 
(Table 1). The temperatures, screw speed and the torque forces were recorded for each 
processed sample. The screw speed used for extrusion was 50-100 rpm with a feed rate of 1 
kg/hr. The EuroLab 16 is contacted to a terminal PC and all processing parameters can be 
controlled through the appropriate software supplied by Thermo Fisher. The extrudates were 
collected in powder forms so no additional down streaming processing were required and 
upon the optimization 180oC was used as the final extrusion temperature. 
     All extruded granules were fed to a Mini Cap capsule filler (Karnavati Engineering ltd, 
India) in line with the extruder in continuous manufacturing platform (Fig. 1). The machine 
output was set at 1500 capsules (0 size) per hour in an automatic mode.  
 
Scanning electron microscopy (SEM) 
The spatial distribution of discreet chemical phases was evaluated using a cold-cathode 
field-emission gun scanning electron microscope (Hitachi SU8030 FEG-SEM, Japan). The 
samples were placed on double-sided carbon adhesive tabs and coated with carbon (Edwards 
306 high vacuum carbon evaporation) before SEM analysis. The surface analysis to 
characterize the morphology of the pellets was evaluated using SEM at a nominal 
magnification of 1000× (area = 0.127 mm × 0.095 mm). The accelerating voltage of the 
incident electron beam was set at 8 kV. This value was selected in order to minimize beam 
damage to the sample while maintaining adequate excitation. 
 
Particle size analysis 
The particle size distributions of the granules were determined using a Mastersizer 2000 
laser diffraction instrument (Malvern Instruments, UK) with a dry powder sample dispersion 
accessory (Scirocco 2000) and pressure at 0.5 bar and a vibration feed rate of 50%. Samples 
were run in triplicates. Mastersizer 2000 software was used for data evaluation. 
 
Thermal analysis 
A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 
(DSC) was used to carry out DSC runs of pure actives, physical mixtures and extrudates. 2-5 
mg of sample was placed in sealed aluminium pans with pierced lids.  The samples were 
  
heated at 10°C/min from 0°C to 220°C under dry nitrogen atmosphere and reheated at the 
same heating rate. 
Thermogravimetric analysis (TGA) measurements were conducted synchronously on a 
Q5000 (Thermal Analysis Company, USA). The vesicle samples were frozen in a liquid 
nitrogen bath followed by a vacuum freeze-drying step before TGA and DSC measurements. 
The lyophilized samples were placed into the alumina crucible with nitrogen as the reference. 
The heating-rate was 10oC/min from 25 to 250oC. 
 
X-ray powder diffraction (XRPD) 
XRPD was used to determine the solid state of pure active substances, physical 
mixtures and extruded materials using a Bruker D8 Advance (Germany) in theta-theta mode. 
For the study purposes a Cu anode at 40kV and 40Ma, parallel beam Goebel mirror, 0.2 mm 
exit slit, LynxEye Position Sensitive Detector with 3° opening (LynxIris at 6.5 mm) and 
sample rotation at 15 rpm were used. Each sample was scanned from 2 to 40° 2Ɵ with a step 
size of 0.02° 2Ɵ and a counting time of 0.1 seconds per step;  176 channels active on the PSD 
making a total counting time of 35.2 seconds per step. 
 
In-line Near Infra-Red (NIR) monitoring   
Near infrared spectrometry was performed during extrusion using an Antaris II NIR 
spectrometer (Thermo Scientific, UK) equipped with a halogen NIR source and InGaAs 
detector. The instrument utilised a fibre optic probe which was connected to the NIR 
spectrometer and used for in-line monitoring. NIR spectra were collected in real-time during 
the entire extrusion process via a fibre optic diffuse reflectance probe. All NIR in-line spectra 
were continuously collected using the RESULT Integration software (Version 3.0 Thermo 
Scientific, UK). Each spectrum was acquired by averaging 32 scans with a resolution of       
16 cm−1 over the 4,000–10,000 cm−1 wavenumber range. The acquisition of a full spectrum 
took approximately 16 s. The spectral pre-processing was performed using the TQ Analyst 
software (Version 8.6.12 Thermo Scientific, UK). 
 
In vitro dissolution study 
In vitro dissolution studies 26 were conducted in 900 ml of 0.2 M dihydrogen-sodium-
orthophosphate (pH adjusted with NaOH to 6.8) for 2 h using a Varian 705 DS dissolution 
paddle apparatus (Varian Inc. North Carolina, US) at 100 rpm. All formulations were directly 
dropped in the vessels without filling them in a capsule (n=3). Dissolution bath and vessels 
  
were equilibrated to 37 ± 0.5°C. At predetermined time intervals, samples were withdrawn 
for HPLC assay.  
 
HPLC analysis  
 The release of TLT was determined by using HPLC, Agilent Technologies system 1200 
series. A HYCHROME S50DS2-4889 (5 µm x 150 mm x 4mm) column was used for the 
HPLC analysis. The wavelength was set at 340 nm. The mobile phase consisted of 
methanol/water/triethyl amine (75/25/0.2 v/v) and the flow rate was maintained at 1.0 ml/min 
and the retention time was 2-3 min. Calibration curve was prepared with concentrations 
varying from 10 µg /ml to 50 µg/ml and 20 µl injection volumes. 
 
Results and discussion 
HME processing and capsule manufacturing 
In order to optimize the extrusion processing parameters, various TLT based 
formulations of different ratios and compositions were processed under different extrusion 
temperatures varying from 170-200oC. The solid-state analysis (see below), revealed that 
temperatures above 180oC are the most appropriate for the processing of TLT batches and the 
drug remained stable within the temperature range (melting point of TLT is above 200oC). By 
using inorganic silicates as drug carrier the HME process optimization resulted in the 
production of free flowing granules. NEU is considered an excellent excipient for extrusion 
purposes due to the high flowability (Carr’s index 13), high specific surface area and the drug 
absorbance within the silicate porous network. 23  
The TLT solubility studies conducted using a range of hydrophilic surfactants (data not 
shown) revealed that both Labrafil and Labrasol have the highest solubilisation capacity for 
TLT in buffer solution (pH 6.8). Therefore, these two surfactants were used as hydrophilic 
surfactants and co-processed with NEU at high drug loadings (40-60% w/w ratios) as shown 
in Table 1. The extrusion of NEU in presence of liquid surfactants (10-15% w/w ratios) 
facilitated a complete dry blending resulting in the production of TLT loaded free flowing 
powders. 
The excellent flowability of the extruded powders was also achieved even at 60% drug 
loadings despite the poor flow properties of IND and the surfactants used in the formulations. 
The estimated Carr’s index values of TLT/NEU and TLT/NEU/surfactants extruded powders 
varied from 10-11, which are in the same range of the bulk inorganic NEU. The use of 
inorganic NEU and the process optimization in the absence of the extrusion die eliminated 
  
the downstream processing and provided high throughput of extruded formulations. 
Furthermore, HME was coupled successfully with an auto capsule filler MiniCap to 
manufacture capsules without the addition of other excipients. The process was allowed to 
operate continuously for 3hr and produced 1500 capsules (‘0’ size) per hour.  
  
SEM and particle size analysis 
 SEM analysis was used to investigate the surface morphology of the bulk substances and 
the extruded formulations. As shown in Fig. 2a for all of the TLT/NEU formulations with or 
without surfactants no drug crystals can be identifued on the NEU surface indicating 
excellent extrusion processing. Further observation shows that TLT/NEU extrudates formed 
agglomerates comprising of microstructured particles. The formation of agglomerates where 
the drug substance is adsorbed while the obtained particle size is similar to that of bulk NEU 
can be of great interest for the development of oral dosage forms (e.g. capsules) in a 
continuous manufacturing process without the requirement of further down-streaming 
processing. As shown in Fig. 2b the determined particle size distribution of all extrudates  
and bulk NEU varied from 40 – 300µm (d(0.9) = 300µm). Due to the drug/surfactant 
adsorption in the porous inorganic network no further micronization was required. .   
 
Thermal analysis 
The bulk materials, physical mixtures and extruded formulations were further investigated 
by DSC analysis. As shown in Fig. 3a, pure TLT presented a sharp endotherm corresponding 
to its melting peak at 213oC (H = 155.27 j/g). Synthetic NEU didn’t present any reversible 
thermal transition below 250oC in MTDSC (only a non-reversible thermal transition was seen 
at 165oC), which could be due to the water loss of the two water molecules in NEU structure 
(Supp. Fig. 1).  
 
TLT/NEU (60/40 w/w) physical mixture (F3) showed a sharp endothermic thermal 
transition due to the melting of the drug at 213oC (H = 174.51 J/g) (Fig. 3a). In contrast in 
the extruded formulation a slight sift of the TLT melting endotherm at 211.89oC (H = 
160.01 J/g) was observed.  As shown in similar studies27 of porous carriers the endothermic 
shift simply indicates the co-existence of amorphous and crystalline TLT in the porous 
network. A similar phenomenon was observed in TLT/NEU/LSOL extruded formulation (F5) 
with a significant shift of the melting endotherm towards lower temperatures at 202.37oC. In 
the physical blends of F5, TLT showed a melting peak at 212.19oC, which was shifted at 
  
201.33oC after the extrusion processing. In both cases the shift in the melting peak of TLT 
can be attributed to the presence of surfactant in the system. The liquid LSOL has partially 
solubilized TLP facilitating further adsorption in the inorganic carrier. It can also be seen that 
the melting peaks differ in shape where broader peaks suggest more drug melted within the 
pores. This indicates that the presence of hydrophilic surfactant such as LSOL may have 
played a key role to TLT solubilization during the extrusion process, which in turn is 
expected to show an impact in the in vitro dissolution rates. 
 
Thermo-gravimetric (TGA) analysis was performed to determine any potential material 
weight loss as a function of the increasing temperatures. As can be seen in Fig. 3b bulk TLT 
has not showed any weight loss up to 205oC while bulk NEU showed a net weight loss of 
about 12.0% at 200oC corresponding to the loss of two molecules. A similar thermal 
transition was observed in the MTDSC analysis as mentioned above. The bulk LSOL showed 
weight loss of 5.24% which is expected to not to provide any significant impact in the 
extruded formulations considering only 10% w/w ratio in the final formulation prior to the 
extrusion processing. Both the TLT/NEU and TLT/NEU/LSOL extruded formulations 
exhibited lower weight losses of 5.40% and 3.70% respectively. These weight losses are quite 
lower compared to bulk NUE suggesting that H2O molecules were not completely removed 
when NEU was co-processed with TLT or TLT/LSO. 
 
X-ray powder diffraction (XRPD) studies 
X–ray powder diffraction analysis of bulk substances and extruded granules, was 
performed in order to examine the physical state of the drug substance.  As can be seen in 
Fig. 4 and Supp. Fig. 2 the diffractogram of bulk TLT showed distinct intensity peaks due to 
its crystalline structure at 11.06o, 12.17o, 13.78o, 16.67o, 18.64o, 22.41o, 24.63o, 28.46o, 31.07o 
2θ degrees while NEU appeared as completely amorphous with no crystalline intensity peaks. 
The physical blends of all TLT formulations showed identical peaks without any reduction of 
the peak intensities due to the presence of crystalline TLT. Similarly, all extruded granules 
showed identical peaks at relatively lower intensities suggesting lower degree of crystalline 
TLT and increase of the amorphous content during the extrusion processing even at high 60% 
drug loading.  
 
 
 
  
In- line NIR spectroscopy monitoring  
Off-line NIR spectra of bulk TLT, excipients and physical blends were recorded in order 
to identify the characteristic bands of the bulk substances. An in-line NIR reflectance probe 
was coupled on the HME process to continuously monitor 28, 29 all of the TLT based 
formulations. Furrhet, in-line NIR spectra of the TLT/NEU 60/40 (w/w) formulation were 
recorded during the extrusion at the third mixing zone. The second derivative spectra in Fig. 
5a-d shows a significant peak shift between the NIR spectra of bulk TLT and that in the 
extruded granules. The NIR signal of NEU was flat in the same region suggesting no effect 
on the drug absorption. In Fig. 5a it can be seen that the second derivative NIR spectra 
showed a significant peak shift, particularly in the range of 8800–8900 cm-1, indicating 
potential intermolecular interactions between the drug and the complex silicate. Interestingly, 
the dimer peaks of the bulk TLT at 8800 – 8900 cm-1 disappeared in the extruded granules 
and showed a broad peak, which could be due to the interactions and also could be attributed 
to the increase the amorphicity of the extruded materials.  
 
Furthermore, Fig. 5b shows that a peak at 7095 cm-1 attributed to the –OH stretching first 
overtone of the drug TLT has been shifted to a new position at 7109 cm-1 in the TLT/NEU 
extrudates.  The peak shifting at this position is probably due to the H-bonding between the -
COOH of TLT and the –O group of NEU. 30 There are also two more peaks at 7385 cm-1 and 
7212 cm-1 were shifted from 7402 cm-1 and 7234 cm-1 respectively. These two peaks are 
attributed to the –CH stretching, and the reason of the peak shifting occurs is could be due to 
the formation of weak H-bond (C-H···O) between the drug and the excipient.31  Furthermore, 
another peak at 5206 cm-1 which is attributed to the C=O second overtone has also been 
shifted to 5230 cm-1 (Fig. 5c). This peak shifting is due to the formation of H-bond between 
the –C=O of the drug and the excipient. The amide group (-CONH-R) of the drug was visible 
via an intense peak at 4668 cm-1, which has been slightly shifted and appears broader after 
the extrusion processing (Fig. 5d). This could be attributed to the increase in the amorphicity 
of the drug in the extruded formulations as confirmed by the XRD and DSC studies.  
 
In vitro dissolution studies 
In vitro dissolution studies of TLT formulations were compared with the bulk TLT and 
the commercial formulation (Rizaben®). The studies showed a significant improvement in 
the drug release at phosphate buffer (pH 6.8). As shown in Fig. 6a for the first 60 min the 
TLT/NEU extruded (60% TLT loading w/w) formulation and Rizaben® presented similar 
  
profiles (p>0.05) with release profiles varying from 70–80%. However, after 120min the 
extruded formulation presented 100% TLT dissolution rates while Rizaben® reached a 
maximum of 81-84%. The increase of TLT loading in the extruded formulations did not 
affect the dissolution rates, which were similar as shown in Fig. 6a. It can also be seen that 
the dissolution rate of bulk TLT was approximately 40% after 120 min.  
 
As shown in Fig. 6b for the, co-processed NEU/LSOL extrudates the TLT dissolution 
rates were again similar to Rizaben® at 76% after 30 min but significantly higher after 60 
min. The TLT/NEU/LFIL extrudate showed slower dissolution rates with around 61% for the 
first 60 min compared to TLT/NEULSOL and Rizaben® respectively and 95% at 120 min.  
 
 The observed increase in the dissolution studies of TLT extruded formulations could be 
attributed to the effect of sinalol groups in NEU. As previously reported, NEU generates 
various silanol groups (e.g. free, germinal or associated) when in contact with water render it 
it a potential proton donor as well as a proton acceptor. 22 The existence of free silicic acid 
and ions (Mg2+ and Al3+) in the dissolution media may have played a vital role to cause the 
increase in the dissolution of TLT. Similar results were observed from Bahl et al. 19 for 
indomethacin solid dispersions. In the present study, the increase dissolution rates in the 
presence of LSOL or LFIL within the extruded formulations is due to the solubilising 
capacity of the two surfactants.  However, as shown in Fig. 6b the presence of LSOL in the 
extrudates resulted in better dissolution rates compared to LFIL due to its better solubilizing 
effect on TLT as confirmed by the saturation solubility data (Supp. Fig. 3).  
 
Conclusions 
 In the current study inorganic aluminocilicates were processed with or without 
surfactants and exploited as a suitable drug carrier for continuous extrusion processing to 
produce capsules with enhanced dissolution rates of the poorly water-soluble drug TLT. The 
process comprised of only 3 operational units for continuous extrusion processing followed 
by capsule filling in the absence of any downstream equipment. The process optimization 
resulted in 60% TLT loadings with excellent powder flowability of the extruded 
formulations. Physicochemical characterization showed drug adsorption in the porous 
inorganic network while the present of surfactants increase TLP solubilization within the 
NEU carrier. In vitro dissolution studies revealed a significant increase of the dissolution 
  
rates of TLT compared to that of commercial capsules Rizaben. Inorganic excipients were 
used as a paradigm for drug extrusion though continuous capsule filling.  
 
Conflict of interest  
 The authors report no declaration of interests.  
 
Acknowledgments  
 This work was financially supported by the Fuji Chemical Industry Co., Ltd., Japan. 
 
References 
1. Llusa M, Mohr S, Baumgartner R, Paudel A, Koscher G, Khinast J. Continuous low-
dose feeding of highly active pharmaceutical ingredients in hot-melt extrusion. Drug 
Dev Ind Pharm. 2016; 42(8):1360-4.  
2. Tiwari RV, Patil H, Repka MA. Contribution of hot-melt extrusion technology to 
advance drug delivery in the 21st century. Expert Opin Drug Deliv. 2016; 13(3):451-
64. 
3. Maniruzzaman M, Douroumis D. Continuous manufacturing and process analytical 
tools. Int. J Pharm. 2015; 496 (1):1-2. 
4. Abu-Diak OA, Jones DS, Andrews GP. Understanding the performance of melt-
extruded poly(ethylene oxide)–bicalutamide solid dispersions: Characterisation of 
microstructural properties using thermal, spectroscopic and drug release methods. J 
Pharm Sci. 2012;101 (1): 200–213 
5. Park JB, Prodduturi S, Morott J, Kulkarni VI, Jacob MR, Khan SI, Stodghill SP, Repka 
MA. Development of an antifungal denture adhesive film for oral candidiasis utilizing 
hot melt extrusion technology. Expert Opin. Drug Deliv. 2015; 12 (1): 1–13 
6. Andrews GP, Jones DS. Hot melt extrusion-processing solid solutions?. J. Pharm. 
Pharmacol. 2014; 66 (2): 145–147. 
7. Li L, AbuBaker O, Shao ZJ. Characterization of poly(ethylene oxide) as a drug carrier 
in hot-melt extrusion. Drug Dev Ind Pharm. 2006; 32(8): 991-1002 
8. Jones DS, Margetson DN, McAllister MS, Yu, T, Shu L, McCoy CP, Andrews GP. 
Thermodynamically stable amorphous drug dispersions in amorphous hydrophilic 
polymers engineered by hot melt extrusion. Chem. Eng. Res. 2014; 92(12): 3046 – 54.  
  
9. Liu H, Zhang X, Suwardie H, Wang P, Gogos CG. Miscibility studies of indomethacin 
and Eudragit® E PO by thermal, rheological, and spectroscopic analysis. J Pharm Sci. 
2012;101(6): 2204–2212  
10. Qi S, Belton P, Nollenberger K, Clayden N, Reading M, Craig DQM. Characterization 
and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, 
microscopic and NMR relaxometry study. Pharm. Res. 2010; 27: 1869–1883. 
11. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, McGinity JW, 
Martin C. Pharmaceutical applications of hot-melt extrusion: part I, Drug Dev. Ind. 
Pharm. 2007; 33(9): 909–926. 
12. Tackenberg MW, Krauss R, Marmann A, Thommes M, Schuchmann HP, 
Kleinebudde P. Encapsulation of liquids using a counter rotating twin-screw extruder. 
Eur J Pharm Biopharm. 2015; 89:9-17 
13. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric 
carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J 
Pharm. 2012; 429(1-2): 58-68 
14. Maniruzzaman M, Rana, MM, Boateng JS, Mitchell JC, Douroumis D. Drug Dev Ind 
Pharm. 2013; 39: 218-27. 
15. Gryczke A, Schminke GS, Maniruzzaman M, Beck J, Douroumis D. Development and 
evaluation of orally disintegrating tablets (ODTs) containing ibuprofen granules 
prepared by hot melt extrusion. Colloids Surf B Biointerfaces, 2011; 86: 275-84. 
16. Lang B, McGinity JW, Williams III RO. Hot-melt extrusion – basic principles and 
pharmaceutical applications. Drug Dev Ind Pharm. 2014; 40(9): 1133-55. 
17. Gupta MK, Tseng Y-C, Goldman D, Bogner RH. Hydrogen Bonding with Adsorbent 
during Storage Governs Drug Dissolution from Solid-Dispersion Granules. Pharm Res. 
2002; 19: 1663-72. 
18. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T, Takeichi YI, Azuma M, 
Houchi, H, Minakuchi K. Improvement of solubility and oral bioavailability of a poorly 
water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J. 
Pharm. Sci. 2002; 912: 362–370. 
19. Bahl D, Bogner RH. Amorphization Alone Does Not Account for the Enhancement of 
Solubility of Drug Co-ground with Silicate: The Case of Indomethacin. AAPS 
PharmSciTech. 2008; 9: 146-153. 
  
20. Maclean J, Medina C, Daurio D, Alvarez-Nunez  F, Jona J, Munson E, Nagapudi K. 
Manufacture and performance evaluation of a stable amorphous complex of an acidic 
drug molecule and neusilin. J Pharm Sci. 2011; 100: 3332-44. 
21. Maniruzzaman M, Nair A, Renault M, Nandi U, Scoutaris N, Farnish R, Bradley MS, 
Snowden MJ, Douroumis D. Continuous twin-screw granulation for enhancing the 
dissolution of poorly water-soluble drugs. Int. J Pharm. 2015; 496(1): 52-62. 
22. Maniruzzaman M, Nair A, Scoutaris N, Bradley MS, Snowden M.J, Douroumis D. 
One-step continuous extrusion process for the manufacturing of solid dispersions. Int J 
Pharm. 2015; 496(1): 42-51. 
23. Neuslin® technical brochure; Fuji chemical industry co., ltd., Japan 
(www.neusilin.com): last accessed 05th October 2016. 
24. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid 
dispersion of tranilast with high photostability and improved oral bioavailability. Eur. 
J. Pharm. Sci. 2010; 39: 256-262. 
25. The Society of Japanese Pharmacopoeia: Tranilast. Japanese Orange Book No. 12 
Approved drug products with therapeutic equivalence evaluations¥, Tokyo, Yakuji 
Nippo Ltd., 2002, p 171. 
26. US pharmacopoeia, 2015, 
http://www.pharmacopeia.cn/v29240/usp29nf24s0_m40420.html; last accessed Sep 
2015. 
27. Fatouros, DG, Douroumis D, Nikolakis V, Ntais S, Moschovi,  AM,  Trivedi,  V, 
Khima,  B, Roldo, M, Nazar, H, Cox PA. In vitro and in silico investigations of drug 
delivery via zeolite BEA. J. Mater. Chem. 2011; 21: 7789 
28. Saerens L, Dierickx L, Quinten T, Adriaensens P, Carleer R, Vervaet C, Remon JP, De 
Beer, T. In-line NIR spectroscopy for the understanding of polymer– drug interaction 
during pharmaceutical hot-melt extrusion. Eur. J. Pharm. Biopharm. 2012; 81: 230–
237. 
29. Coates PD, Barnes SE, Sibley MG, Brown EC, Edwards HGM, Scowen IJ. In-process 
vibrational spectroscopy and ultrasound measurements in polymer melt extrusion. 
Polymer. 2003; 44: 5937–5949. 
30. Islam MT, Scoutaris N, Maniruzzaman M., Moradiya HG, Halsey SA, Bradley 
MS, Chowdhry BZ, Snowden MJ, Douroumis D. Implementation of transmission NIR 
as a PAT tool for monitoring drug transformation during HME processing. Eur J 
Pharm Biopharm. 2015; 96: 106-16. 
  
31. Desiraju GR. C-H···O and other weak hydrogen bonds. From crystal engineering to 
virtual screening. Chem. Comm. 2005; 24: 2995-3001. 
 
 
 
 
Table 1: Formulation composition of TLT based formulations 
Formulation TLT 
(w/w) 
NEU 
(w/w) 
LSOL 
(w/w) 
LFIL 
(w/w) 
1 40 60   
2 40 30   
3 60 40   
4 60 25 15  
5 60 25  15 
6 60 30 10  
7 60 30  10 
 
50/170/180/180/180/180/180/180/180oC (Feeder to die) 
Screw speed: 100 rpm, Feed rate: 1 kg/h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figures caption list 
 
Fig. 1 Schematic diagram of manufacturing TLT based capsule in a continuous 
process. 
Fig. 2a SEM images of (a-b) TLT/NEU 60/40 and (c-d) TLT/NEU/LSOL 60/30/10 
extruded formulations. 
Fig. 2b Particle size distribution of TLT extruded formulations comparing to the 
bulk NEU. 
Fig. 3a DSC thermal transitions of bulk TLT, TLT/NEU 60/40, TLT/NEU/LSOL 
60/30/10 and TLT/NEU/LFIL 60/30/10 formulations. 
Fig. 3b TGA thermograms of bulk TLT, NEU, TLT/NEU and TLT/NEU/LSOL 
extruded formulations. 
Fig. 4 XRD difffractograms of bulk TLT, NEU and TLT based physical mixtures 
(PM) and extruded formulations (EXT).  
Fig. 5  (a-d) 2nd derivative NIR spectra of TLT, NEU and TLT/NEU formulations. 
Fig. 6a In vitro TLT dissolution profiles of Rizaben and extruded formulation (n = 
3, pH 6.8). 
Fig. 6b In vitro TLT dissolution profiles of Rizaben and co-processed extruded 
formulations with NEU/LSOL (LFIL) (n=3, pH 6.8). 
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Fig. 6 (a,b) 
